GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioton SA (FRA:7U5) » Definitions » Tariff Resilience Score

Bioton (FRA:7U5) Tariff Resilience Score : 0/10 (As of Jun. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Bioton Tariff Resilience Score?

Bioton has the Tariff Resilience Score of 0, which implies that the company might have .

Bioton has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bioton might have .


Bioton  (FRA:7U5) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bioton Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Bioton's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioton Business Description

Industry
Traded in Other Exchanges
Address
Ul. Staro?ci?ska 5, Warszawa, POL, 02-516
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.

Bioton Headlines

No Headlines